CVS Health sees strong Q1 2025 growth, but risks loom with downgraded revenue guidance and Medicare challenges. Read my ...

CVS stock has an attractive yield and earnings expansion. That makes it worth a look for investors seeking growth and income.

Activist investor Glenview Capital said on Tuesday it had reduced its holdings in CVS Health following the insurer's "healthy ...

CVS Health (NYSE:CVS) reported robust year-over-year growth in Q1 2025 earnings, with significant increases in sales, revenue ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

CVS Health Corp. reported a strong start to 2025, with first-quarter revenue climbing 7%, driven by growth across all business segments.

The post PRISM Stocks making the biggest moves premarket: Microsoft, CVS Health, Meta Platforms, Qualcomm and more appeared first on PRISM MarketView.

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Zepbound's prescription growth has surged ahead of Novo Nordisk's rival GLP-1 weight-loss drug Wegovy in recent months after struggles with supply issues in 2024. CVS's pharmacy benefit ... not ...